Search

Your search keyword '"Guerra, Conceição"' showing total 9 results
Start Over Author "Guerra, Conceição"
9 results on '"Guerra, Conceição"'

1. Data visualization for the Internal Audit function at MC

Author

Marta Sofia Guerra Conceição Teixeira de Moraes and Faculdade de Economia

Subjects
Economia e gestão, Economics and Business, Economia e gestão [Ciências sociais], Economics and Business [Social sciences]
Published
2022

3. Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial

Author

Pedral-Sampaio Diana Brasil, Netto Eduardo Martins, Brites Carlos, Bandeira Antonio Carlos, Guerra Conceição, Barberin Maria Goreth, and Badaró Roberto

Subjects
Tuberculosis, GM-CSF, treatment, Infectious and parasitic diseases, RC109-216, Microbiology, QR1-502
Abstract

It has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GM-CSF) or a placebo, both in combination with anti-tuberculosis chemotherapy. Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months. At the beginning of treatment, rhu-GM-CSF (125µg/M²) was randomly assigned to 16 patients and injected subcutaneously twice weekly for four weeks; the other 15 patients received a placebo. The patients were accompanied in the hospital for two weeks, then monthly on an out patient basis, for 12 months. Clinical outcomes were similar in both groups, with no difference in acid-fast bacilli (AFB) clearance in sputum at the end of the fourth week of treatment. Nevertheless, a trend to faster conversion to negative was observed in the rhu-GM-CSF group until the eighth week of treatment (p=0.07), after which all patients converted to AFB negative. Adverse events in the rhu-GM-CSF group were local skin inflammation and an increase in the leukocyte count after each injection, returning to normal 72 hours after rhu-GM-CSF injection. Three patients developed SGOP and SGPT > 2.5 times the normal values. All patients included in the GM-CSF group were culture negative at six months, except one who had primary TB resistance. None of the patients had to discontinue the treatment in either group. We conclude that rhu-GM-CSF adjuvant immunotherapy could be safely explored in a phase 3 trial with patients who have active tuberculosis.

Published
2003

5. Brazilian Journal of Infectious Diseases

Author

Pedral Sampaio, Diana Brasil, Martins Netto, Eduardo, Brites, Carlos, Bandeira, Antonio Carlos de Albuquerque, Guerra, Conceição, Barberin, Maria Goreth, and Badaró, Roberto José da Silva

Subjects
Treatment, Tuberculosis, GM-CSF
Abstract

p.245-252 Submitted by Texeira Ana (atanateixeira@gmail.com) on 2012-10-15T19:47:35Z No. of bitstreams: 1 Pedral-Sampaio, Diana Brasil.pdf: 46999 bytes, checksum: 4a5641cd8abcd1fcf0d101bbe5188501 (MD5) Made available in DSpace on 2012-10-15T19:47:35Z (GMT). No. of bitstreams: 1 Pedral-Sampaio, Diana Brasil.pdf: 46999 bytes, checksum: 4a5641cd8abcd1fcf0d101bbe5188501 (MD5) Previous issue date: 2003-08 It has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GM-CSF) or a placebo, both in combination with anti-tuberculosis chemotherapy. Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months. At the beginning of treatment, rhu-GM-CSF (125µg/M2) was randomly assigned to 16 patients and injected subcutaneously twice weekly for four weeks; the other 15 patients received a placebo. The patients were accompanied in the hospital for two weeks, then monthly on an out patient basis, for 12 months. Clinical outcomes were similar in both groups, with no difference in acid-fast bacilli (AFB) clearance in sputum at the end of the fourth week of treatment. Nevertheless, a trend to faster conversion to negative was observed in the rhu-GM-CSF group until the eighth week of treatment (p=0.07), after which all patients converted to AFB negative. Adverse events in the rhu-GM-CSF group were local skin inflammation and an increase in the leukocyte count after each injection, returning to normal 72 hours after rhu-GM-CSF injection. Three patients developed SGOP and SGPT > 2.5 times the normal values. All patients included in the GM-CSF group were culture negative at six months, except one who had primary TB resistance. None of the patients had to discontinue the treatment in either group. We conclude that rhu-GM-CSF adjuvant immunotherapy could be safely explored in a phase 3 trial with patients who have active tuberculosis. Salvador

Published
2003
Full Text
View/download PDF

8. Congestive cirrhosis in Osler-Weber-Rendu syndrome: A rare case report.

Author

Leitão P, Carvalho A, Guerra C, Gonçalves J, and Ramos I

Abstract

Hereditary hemorrhagic telangiectasia or Osler-Weber-Rendu syndrome is a rare autosomal dominant vascular disorder characterized by epistaxis, mucocutaneous telangiectasias, and arteriovenous malformations affecting various organs and systems. The liver is a commonly involved organ (74% of patients with hereditary hemorrhagic telangiectasia), although symptomatic liver disease is quite infrequent. In symptomatic cases, clinical manifestations relate most commonly to the predominant type of vascular shunting present (arteriovenous, arterioportal, or portovenous). Clinically, liver disease can manifest as a high-output cardiac failure, portal hypertension, or biliary disease. Imaging plays an important role in diagnosis, characterization, and follow-up of liver involvement, with ultrasound, computed tomography, magnetic resonance imaging, and angiography being useful in this context. We present a case of congestive cirrhosis with florid liver findings in a patient with Osler-Weber-Rendu syndrome. Imaging findings that clinched the diagnosis are reviewed. A brief literature review is also provided.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results